Women’s health is not a niche. It is one of the largest underserved opportunities in healthcare.
This Tuesday, we brought together experts at our office to discuss the women’s health gap and, importantly, the opportunity to do something about it.
The numbers are striking. Women still face longer diagnostic journeys, higher risks of misdiagnosis and significant gaps in treatment across conditions ranging from cardiovascular disease to menopause and Alzheimer’s. At the same time, only 6% of private healthcare funding between 2020 and 2025 went to women’s health, while 44% of European FemTech startups have not yet raised external funding.
That funding gap also represents an investment opportunity. The European women’s health market is already worth around €13 billion, with FemTech growing at more than 17% annually. And this is not an unproven market: more than 500 exit events in women’s health took place globally between 2020 and 2025, around 80% through M&A.
From menopause and digital primary care to AI diagnostics, there is significant room for innovation that can improve health outcomes while building commercially attractive companies.
A big thank you to Annemarie Haverhals for sharing her perspective on women’s health, the gaps that still need to be addressed and the opportunity for investors to play a role in closing them. Because closing the women’s health gap requires more than awareness. It requires capital.
Want to take action in women’s health as well? Join us in investing in the companies tackling these challenges through Borski Fund II.